Literature DB >> 16960169

Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans.

Nicola Pannacciulli1, Joy C Bunt, Juraj Koska, Clifton Bogardus, Jonathan Krakoff.   

Abstract

BACKGROUND: Glucagon-like peptide 1 (GLP-1) is a gut hormone that decreases appetite and promotes satiety. Its role in energy metabolism regulation is still poorly understood.
OBJECTIVE: The aim of the study was to investigate the relation of fasting plasma GLP-1 concentrations to rates of energy expenditure (EE) and substrate oxidation-ie, respiratory quotient (RQ).
DESIGN: Forty-six glucose-tolerant white subjects (22 men, 24 women) aged 18-49 y whose adiposity spanned a wide range [body mass index (in kg/m2): 18.5-50] were studied in an inpatient clinic. Main outcome measures included resting EE and RQ (ventilated hood technique), body composition (dual-energy X-ray absorptiometry), and fasting plasma concentrations of GLP-1, pancreatic polypeptide, glucose, and insulin.
RESULTS: Fasting plasma GLP-1 concentrations were positively associated with resting EE (after adjustment for age, sex, and body composition) and negatively correlated with RQ (after adjustment for age, sex, and percentage body fat) and fasting plasma pancreatic polypeptide concentrations (both before and after adjustment for age, sex, percentage body fat, and fasting plasma glucose and insulin concentrations). Adjustment for fasting plasma pancreatic polypeptide concentrations, a marker of parasympathetic outflow to the gut, attenuated the strength of the association of fasting plasma GLP-1 concentrations with resting EE and RQ.
CONCLUSIONS: Higher fasting plasma GLP-1 concentrations are associated with higher rates of EE and fat oxidation independent of age, sex, and body composition. The autonomic nervous system may have a role in this relation. This effect, along with the established role of GLP-1 in promoting satiety, may further foster its therapeutic potential in the treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960169     DOI: 10.1093/ajcn/84.3.556

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  35 in total

1.  Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

Authors:  Steven B Waters; Brian G Topp; Scott Q Siler; Charles M Alexander
Journal:  J Diabetes Sci Technol       Date:  2009-01

2.  Alterations in energy balance following exenatide administration.

Authors:  David P Bradley; Roger Kulstad; Natalie Racine; Yoram Shenker; Melissa Meredith; Dale A Schoeller
Journal:  Appl Physiol Nutr Metab       Date:  2012-06-26       Impact factor: 2.665

3.  The influence of calcium supplementation on substrate metabolism during exercise in humans: a randomized controlled trial.

Authors:  J T Gonzalez; B P Green; M D Campbell; P L S Rumbold; E J Stevenson
Journal:  Eur J Clin Nutr       Date:  2014-03-19       Impact factor: 4.016

Review 4.  Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.

Authors:  Rasmus M Christensen; Christian R Juhl; Signe S Torekov
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

5.  Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

Authors:  Alessio Basolo; Joshua Burkholder; Kristy Osgood; Alexis Graham; Sarah Bundrick; Joseph Frankl; Paolo Piaggi; Marie S Thearle; Jonathan Krakoff
Journal:  Metabolism       Date:  2018-03-26       Impact factor: 8.694

6.  Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion.

Authors:  Hariom Yadav; Ji-Hyeon Lee; John Lloyd; Peter Walter; Sushil G Rane
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

Review 7.  Surgical weight loss: impact on energy expenditure.

Authors:  David Thivel; Katrina Brakonieki; Pascale Duche; Béatrice Morio; Morio Béatrice; Yves Boirie; Boirie Yves; Blandine Laferrère
Journal:  Obes Surg       Date:  2013-02       Impact factor: 4.129

8.  The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake.

Authors:  Nicola Pannacciulli; Arline D Salbe; Emilio Ortega; Colleen A Venti; Clifton Bogardus; Jonathan Krakoff
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

9.  Association of beta2-adrenergic receptor and insulin receptor substrate-1 polymorphisms with obesity in a Northern Indian population.

Authors:  Neena Srivastava; B R Achyut; Jai Prakash; C G Agarwal; D C Pant; Balraj Mittal
Journal:  Indian J Hum Genet       Date:  2008-05

10.  Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.

Authors:  Susan L Samson; Erica V Gonzalez; Vijay Yechoor; Mandeep Bajaj; Kazuhiro Oka; Lawrence Chan
Journal:  Mol Ther       Date:  2008-09-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.